Lucas KG - Search Results

1

Expansion of cancer germline antigen-specific cytotoxic T lymphocytes for immunotherapy.

Krishnadas DK, Wang Y, Sundaram K, Bai F, Lucas KG. Krishnadas DK, et al. Among authors: lucas kg. Tumour Biol. 2017 Jul;39(7):1010428317701309. doi: 10.1177/1010428317701309. Tumour Biol. 2017. PMID: 28677424 Free article.

2

Cancer testis antigen and immunotherapy.

Krishnadas DK, Bai F, Lucas KG. Krishnadas DK, et al. Among authors: lucas kg. Immunotargets Ther. 2013 Apr 17;2:11-9. doi: 10.2147/ITT.S35570. eCollection 2013. Immunotargets Ther. 2013. PMID: 27471684 Free PMC article. Review.

3

Dendritic cell vaccines: A review of recent developments and their potential pediatric application.

Elster JD, Krishnadas DK, Lucas KG. Elster JD, et al. Among authors: lucas kg. Hum Vaccin Immunother. 2016 Sep;12(9):2232-9. doi: 10.1080/21645515.2016.1179844. Epub 2016 May 31. Hum Vaccin Immunother. 2016. PMID: 27245943 Free PMC article. Review.

4

Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy.

Huang MA, Krishnadas DK, Lucas KG. Huang MA, et al. Among authors: lucas kg. J Immunol Res. 2015;2015:675269. doi: 10.1155/2015/675269. Epub 2015 Oct 26. J Immunol Res. 2015. PMID: 26587548 Free PMC article. Review.

5

Targeting cancer-testis antigens in recurrent pediatric brain tumors.

Krishnadas DK, Bai F, Lucas KG. Krishnadas DK, et al. Among authors: lucas kg. J Neurooncol. 2015 May;123(1):193-5. doi: 10.1007/s11060-015-1765-6. Epub 2015 Apr 9. J Neurooncol. 2015. PMID: 25855497 No abstract available.

6

A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma.

Krishnadas DK, Shusterman S, Bai F, Diller L, Sullivan JE, Cheerva AC, George RE, Lucas KG. Krishnadas DK, et al. Among authors: lucas kg. Cancer Immunol Immunother. 2015 Oct;64(10):1251-60. doi: 10.1007/s00262-015-1731-3. Epub 2015 Jun 24. Cancer Immunol Immunother. 2015. PMID: 26105625 Clinical Trial.

7

Immunotherapy with virus-specific cytotoxic T lymphocytes after organ transplantation.

Lucas KG, Sun Q. Lucas KG, et al. Pediatr Transplant. 2006 Mar;10(2):142-4. doi: 10.1111/j.1399-3046.2006.00493.x. Pediatr Transplant. 2006. PMID: 16573596

8

Adoptive immunotherapy with CMV-specific cytotoxic T lymphocytes for stem cell transplant patients with refractory CMV infections.

Bao L, Cowan MJ, Dunham K, Horn B, McGuirk J, Gilman A, Lucas KG. Bao L, et al. Among authors: lucas kg. J Immunother. 2012 Apr;35(3):293-8. doi: 10.1097/CJI.0b013e31824300a2. J Immunother. 2012. PMID: 22421947 Free PMC article.

9

Wilms' tumor 1-specific cytotoxic T lymphocytes can be expanded from adult donors and cord blood.

Krishnadas DK, Stamer MM, Dunham K, Bao L, Lucas KG. Krishnadas DK, et al. Among authors: lucas kg. Leuk Res. 2011 Nov;35(11):1520-6. doi: 10.1016/j.leukres.2011.06.037. Epub 2011 Jul 19. Leuk Res. 2011. PMID: 21774984

10

Expansion of cytomegalovirus pp65 and IE-1 specific cytotoxic T lymphocytes for cytomegalovirus-specific immunotherapy following allogeneic stem cell transplantation.

Bao L, Dunham K, Stamer M, Mulieri KM, Lucas KG. Bao L, et al. Among authors: lucas kg. Biol Blood Marrow Transplant. 2008 Oct;14(10):1156-1162. doi: 10.1016/j.bbmt.2008.07.014. Biol Blood Marrow Transplant. 2008. PMID: 18804046 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results